Product news (13 February 2010)
SPCs for medicines are available online
Herceptin (trastuzumab; Roche) is now indicated, in combination with capecitabine or 5-fluorouracil and cisplatin, for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction and who have not received prior anti-cancer treatment for their metastatic disease.
For this indication Herceptin should be administered as an initial loading dose of 8mg/kg followed by 6mg/kg three weeks later and then 6mg/kg repeated at three-weekly intervals administered as infusions.
Orencia (abatacept; Bristol-Myers Squibb) is now licensed, in combination with methotrexate, for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in patients of six years of age or older who have had an insufficient response to other disease-modifying antirheumatic drugs, including methotrexate.
The recommended dose for patients aged six to 17 years is 10mg/kg in children weighing less than 75kg.
For those weighing more than 75kg the adult dosing regimen should be followed, to a maximum dose of 1,000mg.
Dorzolamide eye drops 2 per cent are now available from Teva.
1 x 5ml bottle, £6.33
Lercanidipine film-coated tablets are now available from Teva.
28 x 10mg, £5.70
28 x 20mg, £10.82
All strengths of Beclazone (beclometasone diproprionate) pressurised metered dose inhalers will be discontinued by Teva on 31 March 2010.
Further information from Teva medical information department on 020 7540 7117.
Calci-plus, a calcium carbonate, vitamin D3 and magnesium formulation is now available from Forum Health.
1 x 30 tablets, £4.99
Citation: The Pharmaceutical Journal URI: 10996261